Can a DNA test predict who will respond to cancer immunotherapy?
NCT ID NCT05515796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to see if the test could identify who would have a complete response, meaning no cancer remains after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (immunotherapy drug) combined with chemotherapy (CapeOx) and/or trastuzumab and radiotherapy
What this could lead to
If successful, this could lead to a way to predict which patients will benefit from immunotherapy before treatment, improving outcomes for gastrointestinal cancers.
What could go wrong
This is a Phase 2 trial with 189 participants, so results are still early. The prediction model may not prove accurate enough for widespread use, and immunotherapy can cause serious immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Army Medical Center
Chongqing, Other (Non U.s.), 400000, China